PLANO, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the second quarter ended June 30, 2017.
Highlights
Record consolidated revenues of $7.2 million, including total Algovita® sales of $5.5 million Completed FDA regulatory submission for full-body MRI-conditional approval for the Algovita SCS system
